Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
MOUNTAIN VIEW, Calif., Aug. 26 /PRNewswire/ -- The 2008 European Gene Expression Targeting Platform Technology Innovation Award is presented to Israel-based Vascular Biogenics Ltd. for developing the Vascular Targeting System (VTS(TM)). This unique platform has facilitated novel advancements in gene expression-based treatments where angiogenesis is an explicit feature.
"The VTS(TM) platform is a potent and flexible technology permitting the limitation of gene expression to endothelial cells undergoing angiogenesis," explains Frost & Sullivan Research Analyst Prasanna Vadhana Kannan. "The uniqueness of the VTS(TM) platform can be utilised for the technological advancement and commercialisation of novel treatments targeting life-threatening diseases where angiogenesis occurs."
The innovative gene expression targeting platform technology essentially facilitates control of gene expression to the zones where angiogenesis is taking place to either promote the formation or destroy the newly formed blood vessels. It represents a promising tool for targeted treatment of pathological diseases, supported by the effective delivery of therapies solely to diseased tissues, avoiding harm to the body's healthy tissues.
Till date, the VTS(TM) platform has been used in generating two chief therapeutic drug candidates mainly dependent upon inserted genes, pro-apoptotic and pro-angiogenic signals. The two developmental products based on the VTS(TM) technology are GT-111, an anti-angiogenic cancer therapy, which has the potential to be utilised as a relatively broad-spectrum anticancer agent effective in different types of solid tumours where vascularisation is of primary concern and GT-211, which is a pro-angiogenic therapy for ischemic diseases.
"Both products are ideally designed for effectively stimulating the growth and maturity of new blood vessels, thus aiding in enhancing the VTS(TM) platform's efficacy in thwarting areas that suffer from lack of blood flow due to the obstruction of the existing blood vessel," notes Kannan. "The other clinical stage products being designed by the company include a broad array of small molecule drugs targeting anti-inflammatory disorders as well as diseases of the arteries."
Vascular Biogenics has been able to build a broad pipeline of small molecules that specifically target inflammatory disorders. Moreover, the company has several families of patents that have found application in North America, Europe and south East Asia.
Frost & Sullivan's Technology Innovation Award is bestowed upon a company (or individual) that has carried out new research, which has resulted in innovation(s) that have or are expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. This award recognises the quality and depth of a company's research and development programme as well as the vision and risk-taking that enabled it to undertake such an endeavour.
Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
About Vascular Biogenics Ltd.
Vascular Biogenics Ltd. (VBL) is a clinical stage biopharmaceutical company committed to the development and commercialization of novel treatments for both Atherosclerosis (the cause of heart attack, stroke and other cardiovascular events) and cancer. VBL has developed a new family of anti-inflammatory drugs for chronic inflammatory diseases, such as Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis and Inflammatory Bowel Disease. VBL has also developed the Vascular Targeting System (VTSTM), a new platform technology targeting the formation of new blood vessels, a fundamental factor in the development of cancer and other pathological diseases. The VTSTM enables the safe delivery of potent compounds to the disease tissue only, without permanently harming the body's healthy tissue. For more information about Vascular Biogenics Ltd visit http://www.vbl.co.il.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit http://www.frost.com.
CONTACT: Ari Manoach - CFO of Vascular Biogenics Ltd., 972-3-6346450,
ari@vbl.co.il; or Jasmine Malone - Promotions Coordinator of Frost &
Sullivan, 0044 207 915 7869, jasmine.malone@frost.com
Web site: http://www.frost.com/